Knight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Buys 351,000 Shares

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan acquired 351,000 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The stock was acquired at an average price of C$5.25 per share, with a total value of C$1,842,750.00.

Sime Armoyan also recently made the following trade(s):

• On Monday, January 22nd, Sime Armoyan sold 28,200 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.75, for a total transaction of C$162,150.00.
• On Friday, January 19th, Sime Armoyan sold 91,000 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.75, for a total transaction of C$523,250.00.

Knight Therapeutics Stock Up 0.2 %

Shares of TSE GUD opened at C$5.44 on Thursday. The company has a market capitalization of C$550.36 million, a P/E ratio of -34.00, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.49. Knight Therapeutics Inc. has a 52-week low of C$4.28 and a 52-week high of C$5.75. The company has a debt-to-equity ratio of 9.25, a quick ratio of 1.79 and a current ratio of 3.20. The company’s 50 day moving average price is C$5.46 and its 200-day moving average price is C$5.12.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Royal Bank of Canada raised their price target on shares of Knight Therapeutics from C$6.50 to C$7.00 and gave the stock an “outperform” rating in a report on Friday, March 22nd. Raymond James boosted their price target on shares of Knight Therapeutics from C$7.00 to C$7.50 and gave the stock an “outperform” rating in a research report on Wednesday, March 6th.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.